Publications

Introduction

1. Glioblastoma (GBM) is the most prevalent and aggressive primary brain tumor type with an abysmal prognosis. a. GBM features an immunologically dampened tumor microenvironment and limited neoantigen production. b. Novel therapeutic strategies for GBM are urgently needed.
2. A well-characterized GBM-associated mutation can elicit an anti-tumor immune response: The EGFRvIII mutation.
   1. The cancer-driver mutation is detected in approximately 30% of patients at the time of diagnosis and plays a pivotal role in the emergence of GBM.
   2. Its highly immunogenic nature represents an ideal focal point for cutting-edge mRNA-LNP candidate therapeutics.
   3. (CAR)–T cells directed against EGFRvIII have shown promise in a phase 1 study for GBM treatment, paving the way for a vaccination-based approach.

Read Full Article Here